As announced on 4 August 2020, Navamedic completed the acquisition of the
marketing authorisations in the Nordics for a portfolio of antibiotics for
intravenous injection or infusion in a hospital setting with an annual turnover
of approximately NOK 25 million.

Antibiotics for hospital use are in the Nordics mostly purchased through
national or regional tenders, wherein suppliers of the products compete to win
the entire supply for periods of two years. The decision is based upon a set of
pre-defined criteria including price, product characteristics, user
friendliness, security of supply, and environmental aspects. The environmental
aspects have been given increasing importance over the last years.

Navamedic is pleased to announce that it has won the tender for the entire
Norwegian market for four major antibiotics for the period from February 2022 to
February 2024. The winning factors were environmental aspects and user
friendliness. This tender will secure a substantial amount of the projected
sales volumes for the Navamedic antibiotics portfolio through 2023.

"We are pleased to win our first antibiotics tender and delighted to see that
our focus on environmental aspects and user friendliness has paid off," says
Kathrine Gamborg Andreassen, CEO of Navamedic. "Together with our partner and
shareholder, ACS Dobfar, we have invested in state-of-the-art environmental
documentation and user friendly packaging".

For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
+47 951 78 680          kathrine@navamedic.com

Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71       alexander.lidmejer@navamedic.com

About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com